[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:chronic-graft-versus-host-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":145,"states":146},"Chronic Graft Versus Host Disease",22,20,[8,16,23,29,35,41,47,53,60,66,72,78,84,91,97,103,109,115,120,126,131,138],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05531786","Phase I\u002FII Study of Pacritinib, A JAK2\u002FIRAK1\u002FCSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:43.501109Z","2026-07-05T05:32:16.804024Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04710576","A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)",[20],"Phase 2","2026-08-26T02:16:01.910993Z","2026-06-17T02:29:30.055657Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07116031","A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)",[20],"2026-08-26T02:18:39.640967Z","2026-06-16T05:54:07.933068Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07011810","Axatilimab for Sclerotic Chronic Graft-versus-Host Disease",[20],"2026-08-26T02:18:22.309547Z","2026-05-05T02:43:29.726626Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05922761","BElumosudil for Bronchiolitis Obliterans Prevention\u002FTherapy (BEBOP)",[20],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.642353Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06663722","Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease",[20],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:28.819869Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06619561","A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)",[20],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:28.402371Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT06233110","Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD",[57],"Phase 1","2026-08-26T02:18:46.137046Z","2026-05-05T02:43:26.952984Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05996627","Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease",[20],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.922510Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06046248","Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease",[20],"2026-08-26T02:15:15.642947Z","2026-05-05T02:43:26.725071Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06660355","Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy",[20],"2026-08-26T02:18:30.351130Z","2026-04-29T02:57:57.087093Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[12],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":89,"content_modified":90},"NCT01804686","A Long-term Extension Study of PCI-32765 (Ibrutinib)",[88],"Phase 3","2026-08-26T02:17:12.307088Z","2026-05-05T02:43:28.838066Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07325253","A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET\u002FCT Imaging With Chronic Graft Versus Host Disease Manifestations",[20],"2026-08-26T02:15:57.572488Z","2026-07-05T05:32:16.674700Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07127926","Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD",[],"2026-08-26T02:16:52.995882Z","2026-05-13T02:55:06.656438Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05919511","Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.393403Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05866302","Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.389502Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":58,"content_modified":119},"NCT00092235","Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease",[],"2026-05-13T02:55:06.031033Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05041140","Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment",[],"2026-08-26T02:15:40.343619Z","2026-05-13T02:55:06.280232Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":107,"content_modified":130},"NCT05943964","Virtual Rehabilitation in HCT",[],"2026-05-05T02:43:26.959792Z",{"nct_id":132,"title":133,"phases":134,"status":135,"updated_at":136,"content_modified":137},"NCT07733141","Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease",[],"NOT_YET_RECRUITING","2026-08-26T02:17:54.420226Z","2026-07-30T01:46:14.453657Z",{"nct_id":139,"title":140,"phases":141,"status":142,"updated_at":143,"content_modified":144},"NCT04431479","Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:03:43.088338Z","2026-05-13T02:55:06.248895Z",[],[147,151,154,158,161,164,168,172,175,178,182,185,188,192,195,198,201,204,208,211,214,217],{"state":148,"count":149,"slug":150},"California",10,"california",{"state":152,"count":149,"slug":153},"Texas","texas",{"state":155,"count":156,"slug":157},"Florida",9,"florida",{"state":159,"count":156,"slug":160},"Massachusetts","massachusetts",{"state":162,"count":156,"slug":163},"Washington","washington",{"state":165,"count":166,"slug":167},"Georgia",7,"georgia",{"state":169,"count":170,"slug":171},"Michigan",6,"michigan",{"state":173,"count":170,"slug":174},"New York","new-york",{"state":176,"count":170,"slug":177},"Pennsylvania","pennsylvania",{"state":179,"count":180,"slug":181},"Illinois",5,"illinois",{"state":183,"count":180,"slug":184},"North Carolina","north-carolina",{"state":186,"count":180,"slug":187},"Ohio","ohio",{"state":189,"count":190,"slug":191},"Kansas",4,"kansas",{"state":193,"count":190,"slug":194},"Maryland","maryland",{"state":196,"count":190,"slug":197},"Oregon","oregon",{"state":199,"count":190,"slug":200},"Tennessee","tennessee",{"state":202,"count":190,"slug":203},"Virginia","virginia",{"state":205,"count":206,"slug":207},"Minnesota",3,"minnesota",{"state":209,"count":206,"slug":210},"Missouri","missouri",{"state":212,"count":206,"slug":213},"New Jersey","new-jersey",{"state":215,"count":206,"slug":216},"Utah","utah",{"state":218,"count":206,"slug":219},"Wisconsin","wisconsin"]